PE20181302A1 - Nuevos anticuerpos anti-claudina y sus metodos de uso - Google Patents
Nuevos anticuerpos anti-claudina y sus metodos de usoInfo
- Publication number
- PE20181302A1 PE20181302A1 PE2018001064A PE2018001064A PE20181302A1 PE 20181302 A1 PE20181302 A1 PE 20181302A1 PE 2018001064 A PE2018001064 A PE 2018001064A PE 2018001064 A PE2018001064 A PE 2018001064A PE 20181302 A1 PE20181302 A1 PE 20181302A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- antibody
- methods
- conjugate
- cldn
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 239000000562 conjugate Substances 0.000 abstract 2
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Referido a un conjugado de anticuerpo y farmaco (ADC), caracterizado porque comprende un anticuerpo anti-claudina (anti-CLDN) conectando en forma operativa a un agente citotoxico. El conjugado es de forma M-[L-D]n, o una sal farmaceuticamente aceptable, en donde: M es un anticuerpo anti-CLDN; L es un conector opcional; D es un compuesto activo de pirrolobenzodiazepinas (PBD); y n es un numero entero entre 1 y 20. Este conjugado se une a celulas madres de cancer. Tambien se refiere a una composicion farmaceutica, y metodos para usar los mismos en el tratamiento de trastornos proliferativos como cancer endometrial, cancer de ovario, cancer de mama y cancer de pulmon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263542P | 2015-12-04 | 2015-12-04 | |
| US201662427027P | 2016-11-28 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181302A1 true PE20181302A1 (es) | 2018-08-09 |
Family
ID=58797837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001064A PE20181302A1 (es) | 2015-12-04 | 2016-12-02 | Nuevos anticuerpos anti-claudina y sus metodos de uso |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190083645A1 (es) |
| EP (1) | EP3383917A4 (es) |
| JP (1) | JP2019500335A (es) |
| KR (1) | KR20180088445A (es) |
| CN (1) | CN108473588A (es) |
| AU (1) | AU2016364853A1 (es) |
| BR (1) | BR112018011319A2 (es) |
| CA (1) | CA3006738A1 (es) |
| CL (2) | CL2018001481A1 (es) |
| CO (1) | CO2018005752A2 (es) |
| CR (1) | CR20180348A (es) |
| DO (1) | DOP2018000138A (es) |
| EC (1) | ECSP18049762A (es) |
| HK (1) | HK1254743A1 (es) |
| IL (1) | IL259681A (es) |
| MA (1) | MA43385A (es) |
| MX (1) | MX2018006782A (es) |
| PE (1) | PE20181302A1 (es) |
| PH (1) | PH12018501153A1 (es) |
| RU (1) | RU2018124319A (es) |
| SG (1) | SG11201804673WA (es) |
| TW (1) | TW201726175A (es) |
| WO (1) | WO2017096163A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CN109790222B (zh) | 2016-07-08 | 2022-03-15 | 克莱格医学有限公司 | 抗密蛋白18a2的抗体及其应用 |
| EP3668874B1 (en) * | 2017-08-18 | 2021-12-22 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CA3073331A1 (en) * | 2017-09-02 | 2019-03-07 | Abbvie Inc. | Anti-egfr antibody drug conjugates (adc) and uses thereof |
| AU2018326878A1 (en) * | 2017-09-02 | 2020-03-19 | Abbvie Inc. | Anti-EGFR antibody drug conjugates (ADC) and uses thereof |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| CN112203696A (zh) * | 2018-05-25 | 2021-01-08 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| EP3924389A4 (en) | 2019-02-15 | 2023-06-14 | Integral Molecular, Inc. | CLAUDIN-6 ANTIBODIES AND THEIR USES |
| SG11202109986TA (en) | 2019-03-20 | 2021-10-28 | Univ California | Claudin-6 antibodies and drug conjugates |
| EP3950061A4 (en) | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY CONJUGATE-PYRROLOBENZODIAZEPINE DERIVATIVE |
| MX2022005452A (es) | 2019-11-05 | 2022-07-27 | Lanova Medicines Ltd | Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2. |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR102451185B1 (ko) * | 2021-08-05 | 2022-10-07 | 환인제약 주식회사 | 도네페질 함유 지속방출형 미립구 |
| CN114878728A (zh) * | 2022-05-06 | 2022-08-09 | 浙江大学 | 一种新型的抗体肽图检测还原方法 |
| TW202430574A (zh) | 2022-11-30 | 2024-08-01 | 美商積分分子股份有限公司 | 針對密連蛋白６之抗體，包括其雙特異性格式 |
| US12403202B2 (en) | 2023-05-25 | 2025-09-02 | The Regents Of The University Of California | Dosage of claudin-6 conjugates for cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4833663B2 (ja) * | 2003-12-31 | 2011-12-07 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | Ｃ２−フルオロピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン二量体 |
| US7189710B2 (en) * | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| EA024118B1 (ru) * | 2010-04-15 | 2016-08-31 | Сиэтл Дженетикс, Инк. | Конъюгаты пирролбензодиазепина направленного действия |
| JP5993093B2 (ja) * | 2012-10-12 | 2016-09-14 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン類およびその複合体 |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| PE20160870A1 (es) * | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
-
2016
- 2016-12-02 PE PE2018001064A patent/PE20181302A1/es unknown
- 2016-12-02 US US15/781,110 patent/US20190083645A1/en not_active Abandoned
- 2016-12-02 MA MA043385A patent/MA43385A/fr unknown
- 2016-12-02 CR CR20180348A patent/CR20180348A/es unknown
- 2016-12-02 CN CN201680077475.8A patent/CN108473588A/zh active Pending
- 2016-12-02 HK HK18113756.7A patent/HK1254743A1/zh unknown
- 2016-12-02 JP JP2018528056A patent/JP2019500335A/ja active Pending
- 2016-12-02 BR BR112018011319A patent/BR112018011319A2/pt not_active Application Discontinuation
- 2016-12-02 WO PCT/US2016/064617 patent/WO2017096163A1/en active Application Filing
- 2016-12-02 EP EP16871574.6A patent/EP3383917A4/en not_active Withdrawn
- 2016-12-02 MX MX2018006782A patent/MX2018006782A/es unknown
- 2016-12-02 TW TW105140027A patent/TW201726175A/zh unknown
- 2016-12-02 RU RU2018124319A patent/RU2018124319A/ru not_active Application Discontinuation
- 2016-12-02 CA CA3006738A patent/CA3006738A1/en not_active Abandoned
- 2016-12-02 SG SG11201804673WA patent/SG11201804673WA/en unknown
- 2016-12-02 AU AU2016364853A patent/AU2016364853A1/en not_active Abandoned
- 2016-12-02 KR KR1020187018615A patent/KR20180088445A/ko not_active Withdrawn
-
2018
- 2018-05-29 IL IL259681A patent/IL259681A/en unknown
- 2018-05-31 CO CONC2018/0005752A patent/CO2018005752A2/es unknown
- 2018-05-31 PH PH12018501153A patent/PH12018501153A1/en unknown
- 2018-06-01 DO DO2018000138A patent/DOP2018000138A/es unknown
- 2018-06-01 CL CL2018001481A patent/CL2018001481A1/es unknown
- 2018-07-03 EC ECSENADI201849762A patent/ECSP18049762A/es unknown
-
2019
- 2019-01-24 CL CL2019000189A patent/CL2019000189A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019500335A (ja) | 2019-01-10 |
| CA3006738A1 (en) | 2017-06-08 |
| MA43385A (fr) | 2018-10-10 |
| HK1254743A1 (zh) | 2019-07-26 |
| BR112018011319A2 (pt) | 2018-12-04 |
| MX2018006782A (es) | 2018-11-09 |
| PH12018501153A1 (en) | 2019-01-28 |
| CR20180348A (es) | 2018-08-23 |
| ECSP18049762A (es) | 2018-07-31 |
| KR20180088445A (ko) | 2018-08-03 |
| IL259681A (en) | 2018-07-31 |
| SG11201804673WA (en) | 2018-06-28 |
| WO2017096163A1 (en) | 2017-06-08 |
| TW201726175A (zh) | 2017-08-01 |
| CL2018001481A1 (es) | 2018-08-24 |
| EP3383917A1 (en) | 2018-10-10 |
| US20190083645A1 (en) | 2019-03-21 |
| EP3383917A4 (en) | 2019-08-21 |
| CL2019000189A1 (es) | 2019-06-07 |
| CO2018005752A2 (es) | 2018-06-12 |
| DOP2018000138A (es) | 2018-12-31 |
| CN108473588A (zh) | 2018-08-31 |
| AU2016364853A1 (en) | 2018-06-21 |
| RU2018124319A (ru) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181302A1 (es) | Nuevos anticuerpos anti-claudina y sus metodos de uso | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| PH12020500675A1 (en) | Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| PH12018500285A1 (en) | Bridge linkers for conjugation of a cell-binding molecule | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| PE20191403A1 (es) | Anticuerpos anti-ox40 y sus usos | |
| CL2018003290A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| NZ728072A (en) | Modulators of toll-like receptors for the treatment of hiv | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| EP3524267A4 (en) | THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE | |
| WO2015118030A3 (en) | Antibody-drug conjugates and immunotoxins | |
| MX2018010546A (es) | Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3). | |
| AR078470A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| HK1247789A1 (zh) | 用於治療水腫的組合物和方法 | |
| MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. |